Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents

Publication Date: June 4, 2019

Key Points

Key Points

Use of erythropoiesis-stimulating agents (ESAs) to manage anemia raises hemoglobin levels and reduces the need for red blood cell transfusions but increases the risk of thromboembolic events.

ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.

Treatment

...atment

...nical circumstances ESAs may be offered to...


...t be offered to patients with chemothera...


...ld not be offered to most patients with non-ch...


...may be offered to patients with lower risk m...


...tients with myeloma, non-Hodgkin’s lymphoma, o...


...offering an ESA, clinicians should conduct an a...


...he Expert Panel considers epoetin beta a...


...se the risk of thromboembolism, and...


...mended that starting and modifying doses of E...


...ncreased to the lowest concentration n...


...d be discontinued in patients who d...


...eplacement may be used to improve hemoglobin res...


.... Suggested Baseline Investigations for Anemia in...


...able 2. ESA Adult DosingHaving troubl...


...e 3. Estimated Prices of ESAs and Supplemental...